nChroma Bio’s workforce are facing a second round of layoffs in 12 months, with the Boston biotech halving its headcount and scrapping a trial of its lead hepatitis asset.
The company had been evaluating the liver-directed epigenetic silencer, dubbed CRMA-1001, in a phase 1/2 study as a potential “functional cure” for chronic hepatitis B virus (HBV) infection. The compound is designed to modify the physical structure of the hepatitis virus’ DNA in order to silence its genome.
The study only kicked off in January, but the company announced in a Wednesday LinkedIn post that it has halted enrolment and is “evaluat[ing] strategic alternatives for advancing its programs.”
“Our conviction in the science and our platform remains strong,” nChroma continued. “Our focus remains on finding the best path forward to maximize the potential of these programs and bring meaningful new treatment options to patients.”
As part of this process, the company explained it had “made the difficult decision to restructure the organization.”
A spokesperson told Fierce that in practice this means “roughly half” of the biotech’s employees will be leaving. The company wouldn’t share exact figures on the number of individuals who will be affected.
The remaining employees will be focused on the company’s next-gen preclinical hepatitis B program, which it has been developing in parallel with CRMA-1001.
This next-gen HBV program “represents a promising opportunity to apply our preclinical and clinical learnings to a product we believe may more effectively and safely target HBV viral replication and sAG immune suppression,” nChroma CEO Jeff Walsh explained in his own LinkedIn post.
nChroma’s origin story can be traced back to a meal in 2024 at Bartaco, a restaurant near nChroma’s Boston offices, between Walsh, who was then CEO of Nvelop, and nChroma CEO Catherine Stehman-Breen, M.D. The two long-time acquaintances realized their two companies could team up to innovate new in vivo delivery methods for genetic medicines.
The companies raised $75 million to support their combined venture and consolidated into nChroma’s offices, with Walsh taking the CEO role and Stehman-Breen initially acting as an advisor to the company.
In November 2025, the company laid off an undisclosed number of employees as it geared up to take CRMA-1001 into the clinic.
Hopes for some form of functional “cure” for HBV became a reality in October when GSK secured approval for its Ionis-partnered antisense oligonucleotide Hibsago.